Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects - PubMed (original) (raw)
Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects
Giovanni Addolorato et al. Expert Opin Drug Saf. 2020 Feb.
Abstract
Introduction: Sodium oxybate (SMO) has been approved in Italy and in Austria for the treatment of alcohol use disorder (AUD). This study describes the cumulative postmarketing and clinical safety experience with SMO in AUD.Areas covered: Safety data for SMO at approved posology in AUD were identified from: (i) the clinical trial registries of the US National Institutes of Health (NIH) and the European Medicines Agency (EMA), (ii) reports from the biomedical literature and (iii) available pharmacovigilance safety information from the EMA.Expert opinion: Safety data from 3 recent large randomized clinical studies (520 participants) and 43 earlier clinical studies (2547 participants) showed that SMO has a good safety profile in AUD patients. The safety profile was confirmed by pharmacovigilance data resulting from 299 013 patients exposed to SMO in Austria and Italy. Main adverse events were transitory dizziness and vertigo. Serious adverse events were rare. No death attributable to SMO has been reported. Risks of abuse or dependence are low in patients without psychiatric comorbidities or poly-drug use. The adverse events of SMO are transitory and do not require discontinuation of treatment. SMO abuse or dependence are extremely rare in patients without psychiatric comorbidities or poly-drug use.
Keywords: Sodium oxybate; alcohol use disorder; pharmacovigilance; post-marketing anaysis; safety.
Similar articles
- Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial.
Guiraud J, Addolorato G, Antonelli M, Aubin HJ, de Bejczy A, Benyamina A, Cacciaglia R, Caputo F, Dematteis M, Ferrulli A, Goudriaan AE, Gual A, Lesch OM, Maremmani I, Mirijello A, Nutt DJ, Paille F, Perney P, Poulnais R, Raffaillac Q, Rehm J, Rolland B, Rotondo C, Scherrer B, Simon N, Skala K, Söderpalm B, Somaini L, Sommer WH, Spanagel R, Vassallo GA, Walter H, van den Brink W. Guiraud J, et al. J Psychopharmacol. 2022 Oct;36(10):1136-1145. doi: 10.1177/02698811221104063. Epub 2022 Jul 7. J Psychopharmacol. 2022. PMID: 35796481 Free PMC article. Clinical Trial. - Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention.
Skala K, Caputo F, Mirijello A, Vassallo G, Antonelli M, Ferrulli A, Walter H, Lesch O, Addolorato G. Skala K, et al. Expert Opin Pharmacother. 2014 Feb;15(2):245-57. doi: 10.1517/14656566.2014.863278. Epub 2013 Nov 28. Expert Opin Pharmacother. 2014. PMID: 24283802 Review. - Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence.
Keating GM. Keating GM. Clin Drug Investig. 2014 Jan;34(1):63-80. doi: 10.1007/s40261-013-0158-x. Clin Drug Investig. 2014. PMID: 24307430 Review. - A Brief Up-Date of the Use of Sodium Oxybate for the Treatment of Alcohol Use Disorder.
Caputo F, Vignoli T, Tarli C, Domenicali M, Zoli G, Bernardi M, Addolorato G. Caputo F, et al. Int J Environ Res Public Health. 2016 Mar 5;13(3):290. doi: 10.3390/ijerph13030290. Int J Environ Res Public Health. 2016. PMID: 26959045 Free PMC article. Review. - Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity.
Caputo F, Francini S, Brambilla R, Vigna-Taglianti F, Stoppo M, Del Re A, Leggio L, Addolorato G, Zoli G, Bernardi M. Caputo F, et al. Eur Neuropsychopharmacol. 2011 Jun;21(6):450-6. doi: 10.1016/j.euroneuro.2010.12.005. Epub 2011 Jan 26. Eur Neuropsychopharmacol. 2011. PMID: 21276717 Clinical Trial.
Cited by
- Sodium Oxybate for Alcohol Dependence: A Network Meta-Regression Analysis Considering Population Severity at Baseline and Treatment Duration.
Guiraud J, Addolorato G, Aubin HJ, Bachelot S, Batel P, de Bejczy A, Benyamina A, Caputo F, Couderc M, Dematteis M, Goudriaan AE, Gual A, Lecoustey S, Lesch OM, Maremmani I, Nutt DJ, Paille F, Perney P, Rehm J, Rolland B, Scherrer B, Simon N, Söderpalm B, Somaini L, Sommer WH, Spanagel R, Walter H, van den Brink W. Guiraud J, et al. Alcohol Alcohol. 2023 Mar 10;58(2):125-133. doi: 10.1093/alcalc/agac070. Alcohol Alcohol. 2023. PMID: 36617267 Free PMC article. Review. - Neurosteroids (allopregnanolone) and alcohol use disorder: From mechanisms to potential pharmacotherapy.
Gatta E, Camussi D, Auta J, Guidotti A, Pandey SC. Gatta E, et al. Pharmacol Ther. 2022 Dec;240:108299. doi: 10.1016/j.pharmthera.2022.108299. Epub 2022 Oct 30. Pharmacol Ther. 2022. PMID: 36323379 Free PMC article. Review. - Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders.
Martins B, Rutland W, De Aquino JP, Kazer BL, Funaro M, Potenza MN, Angarita GA. Martins B, et al. Curr Addict Rep. 2022;9(4):647-659. doi: 10.1007/s40429-022-00432-9. Epub 2022 Aug 15. Curr Addict Rep. 2022. PMID: 35990796 Free PMC article. Review. - Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial.
Guiraud J, Addolorato G, Antonelli M, Aubin HJ, de Bejczy A, Benyamina A, Cacciaglia R, Caputo F, Dematteis M, Ferrulli A, Goudriaan AE, Gual A, Lesch OM, Maremmani I, Mirijello A, Nutt DJ, Paille F, Perney P, Poulnais R, Raffaillac Q, Rehm J, Rolland B, Rotondo C, Scherrer B, Simon N, Skala K, Söderpalm B, Somaini L, Sommer WH, Spanagel R, Vassallo GA, Walter H, van den Brink W. Guiraud J, et al. J Psychopharmacol. 2022 Oct;36(10):1136-1145. doi: 10.1177/02698811221104063. Epub 2022 Jul 7. J Psychopharmacol. 2022. PMID: 35796481 Free PMC article. Clinical Trial. - Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse.
Tay E, Lo WKW, Murnion B. Tay E, et al. Subst Abuse Rehabil. 2022 Feb 9;13:13-23. doi: 10.2147/SAR.S315720. eCollection 2022. Subst Abuse Rehabil. 2022. PMID: 35173515 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous